ARE · Q3 2025 Earnings

Narrative arc: Q2 cautious operating quarter → Q3 broad capitulation across guidance, capital plan, and dividend.

The shift from Q2 to Q3 is not incremental — it is categorical. Last quarter management framed 2H25 as a pressure period within an intact megacampus thesis, with the year-end occupancy band reiterated and the development pipeline being "evaluated for alternative lower-cost investment opportunities." This quarter that evaluation has become explicit curtailment: "we're carefully evaluating on a project by project basis, the $4.2 billion of land subject to capitalization... we will likely pause or curtail activity... capitalization of interest, payroll, and other required costs would cease on that project." Stopping capitalization mid-project is a hard balance-sheet trigger, not a soft re-prioritization — it accelerates the earnings hit it's meant to manage. Q2's "we may slow the 2027 pipeline" has become Q3's "we are stopping projects."

The pricing power narrative inverted. Q2's framing emphasized 53% investment-grade tenants, 7.4-year lease terms, and the 466K sq ft pharma build-to-suit as brand-led wins. This quarter management said the quiet part out loud: "we're going to meet the market... if that means more TIs than traditionally we had to get or a roll down in rent, then we'll do it... we're going to get a premium, but it's not going to be where it was in the old cycle." Q3's GAAP renewal spread of 15.2% printed at the top of the lowered +7–15% FY guide, but management is telling you the magnitude has compressed and TI/free-rent concessions are now the price of tenant retention.

Demand expectations were explicitly reset. Q2 attributed leasing to "high-quality tenant flight" and consolidation rather than market-wide acceleration — defensible but defensive. Q3 admits the hoped-for transmission from capital markets to leasing didn't happen: "we're a little surprised that demand hasn't followed as much... it's not as obvious than maybe in past times." Pairing that with the government shutdown, FDA closure, and stubbornly high cost of capital, management has shifted from "macro persists" (Q2) to "macro is actively blocking tenant decisions" (Q3). The XBI rally was supposed to be the leading indicator; it wasn't.

The dividend disclosure is the loudest signal. Q2 made no reference to dividend review. This quarter's press release includes: "we anticipate that our board of directors will carefully evaluate future dividend levels accordingly." For a REIT whose distribution stability is core to the investor base, telegraphing board review is unusual and precedes — by design — what is being prepared at the December 3 Investor Day. Combined with the leverage covenant being relaxed from ≤5.2x to 5.5–6.0x and the disposition target being withdrawn, the capital plan is being publicly rebuilt in real time.

The venture book is now a headwind, not a contributor. The revised $100–120M FY guide for realized gains implies ~$15M in Q4 — a $17M step-down from the recent run rate. This was unremarked in Q2's narrative; in Q3 it's an acknowledged drag from "prolonged biotech bear market" affecting both the investment portfolio and the customer base.